Utama › Kanser (semua jenis) › Hawaii › Honolulu
Kajian klinikal Kanser (semua jenis) di Honolulu, HI
13 kajian untuk Kanser (semua jenis) sedang mencari peserta di lokasi dalam dan sekitar Honolulu (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Mengambil pesertaFasa 2/3
- Invision, LLC, Honolulu
- University of Hawaii Cancer Center, Honolulu
- Cardiology Associates, Inc, ‘Aiea · 7 mi jauh
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 3
- Kaiser Permanente Moanalua Medical Center /ID# 238363, Honolulu
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Mengambil pesertaFasa 2
- The Queen's Medical Center - POB I, Honolulu
- The Queen's Medical Center - Punchbowl, Honolulu
- The Queen's Medical Center - Kuakini, Honolulu
- dan 1 lagi
Connect for Cancer Prevention Study (Connect)
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Kaiser Permanente Hawaii, Honolulu
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Mengambil pesertaFasa 2
- Hawaii Pacific Neuroscience, Honolulu
A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify Patients at High Risk for Breast Cancer
Mengambil pesertaKajian pemerhatian
- Univercity of Hawaii Cancer Center, Honolulu
Project: Every Child for Younger Patients With Cancer
Mengambil pesertaKajian pemerhatian
- Kapiolani Medical Center for Women and Children, Honolulu
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Mengambil pesertaFasa 3
- Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu
- Queen's Cancer Cenrer - POB I, Honolulu
- Queen's Medical Center, Honolulu
- dan 10 lagi
EXoPERT EMERALD Clinical Study
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- University of Hawaii Cancer Center, Honolulu
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Mengambil pesertaFasa 2/3
- Kaiser Permanente Moanalua Medical Center /ID# 275942, Honolulu
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Mengambil peserta
- Spark M. Matsunaga VA Medical Center, Honolulu
CTNow: A Clinical Trials Education Program for Rural Cancer Patients and Oncology Providers
Mengambil pesertaSukarelawan sihat dialu-alukan
- Univesity of Hawaii Cancer Center, Honolulu
GEMINI-NSCLC: NSCLC Biomarker Study
Mengambil pesertaKajian pemerhatian
- Hawaii Cancer Care, Honolulu
Kajian Kanser (semua jenis) di bandar lain
- Houston, TX121 kajian
- New York City, NY110 kajian
- Boston, MA86 kajian
- Los Angeles, CA73 kajian
- Nashville, TN65 kajian
- Philadelphia, PA59 kajian
- Durham, NC58 kajian
- Washington, DC58 kajian
- Chicago, IL51 kajian
- Seattle, WA49 kajian
- Atlanta, GA49 kajian
- Arlington, VA48 kajian
Kajian lain di Honolulu
- Obesiti13 kajian
- Kanser Payudara12 kajian
- Berat Badan Berlebihan11 kajian
- Kanser Paru-paru Bukan Sel Kecil10 kajian
- Kanser Paru-paru8 kajian
- Leukemia Mieloid Akut7 kajian
- Diabetes Jenis 27 kajian
- Kanser Ovari7 kajian
- Kanser Pankreas7 kajian
- Neuroblastoma6 kajian
- Kanser Prostat5 kajian
- Limfoma Burkitt5 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.